Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. (19th January 2021)
- Record Type:
- Journal Article
- Title:
- Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. (19th January 2021)
- Main Title:
- Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics
- Authors:
- Mason, Claire Y
Kanitkar, Tanmay
Richardson, Charlotte J
Lanzman, Marisa
Stone, Zak
Mahungu, Tabitha
Mack, Damien
Wey, Emmanuel Q
Lamb, Lucy
Balakrishnan, Indran
Pollara, Gabriele - Abstract:
- Abstract: Background: COVID-19 is infrequently complicated by bacterial co-infection, but antibiotic prescriptions are common. We used community-acquired pneumonia (CAP) as a benchmark to define the processes that occur in bacterial pulmonary infections, testing the hypothesis that baseline inflammatory markers and their response to antibiotic therapy could distinguish bacterial co-infection from COVID-19. Methods: Retrospective cohort study of CAP (lobar consolidation on chest radiograph) and COVID-19 (PCR detection of SARS-CoV-2) patients admitted to Royal Free Hospital (RFH) and Barnet Hospital (BH), serving as independent discovery and validation cohorts. All CAP and >90% COVID-19 patients received antibiotics on hospital admission. Results: We identified 106 CAP and 619 COVID-19 patients at RFH. Compared with COVID-19, CAP was characterized by elevated baseline white cell count (WCC) [median 12.48 (IQR 8.2–15.3) versus 6.78 (IQR 5.2–9.5) ×10 6 cells/mL, P < 0.0001], C-reactive protein (CRP) [median 133.5 (IQR 65–221) versus 86.0 (IQR 42–160) mg/L, P < 0.0001], and greater reduction in CRP 48–72 h into admission [median ΔCRP −33 (IQR −112 to +3.5) versus +14 (IQR −15.5 to +70.5) mg/L, P < 0.0001]. These observations were recapitulated in the independent validation cohort at BH (169 CAP and 181 COVID-19 patients). A multivariate logistic regression model incorporating WCC and ΔCRP discriminated CAP from COVID-19 with AUC 0.88 (95% CI 0.83–0.94). Baseline WCC >8.2 × 10Abstract: Background: COVID-19 is infrequently complicated by bacterial co-infection, but antibiotic prescriptions are common. We used community-acquired pneumonia (CAP) as a benchmark to define the processes that occur in bacterial pulmonary infections, testing the hypothesis that baseline inflammatory markers and their response to antibiotic therapy could distinguish bacterial co-infection from COVID-19. Methods: Retrospective cohort study of CAP (lobar consolidation on chest radiograph) and COVID-19 (PCR detection of SARS-CoV-2) patients admitted to Royal Free Hospital (RFH) and Barnet Hospital (BH), serving as independent discovery and validation cohorts. All CAP and >90% COVID-19 patients received antibiotics on hospital admission. Results: We identified 106 CAP and 619 COVID-19 patients at RFH. Compared with COVID-19, CAP was characterized by elevated baseline white cell count (WCC) [median 12.48 (IQR 8.2–15.3) versus 6.78 (IQR 5.2–9.5) ×10 6 cells/mL, P < 0.0001], C-reactive protein (CRP) [median 133.5 (IQR 65–221) versus 86.0 (IQR 42–160) mg/L, P < 0.0001], and greater reduction in CRP 48–72 h into admission [median ΔCRP −33 (IQR −112 to +3.5) versus +14 (IQR −15.5 to +70.5) mg/L, P < 0.0001]. These observations were recapitulated in the independent validation cohort at BH (169 CAP and 181 COVID-19 patients). A multivariate logistic regression model incorporating WCC and ΔCRP discriminated CAP from COVID-19 with AUC 0.88 (95% CI 0.83–0.94). Baseline WCC >8.2 × 10 6 cells/mL or falling CRP identified 94% of CAP cases, and excluded bacterial co-infection in 46% of COVID-19 patients. Conclusions: We propose that in COVID-19, absence of both elevated baseline WCC and antibiotic-related decrease in CRP can exclude bacterial co-infection and facilitate antibiotic stewardship efforts. … (more)
- Is Part Of:
- Journal of antimicrobial chemotherapy. Volume 76:Number 5(2021)
- Journal:
- Journal of antimicrobial chemotherapy
- Issue:
- Volume 76:Number 5(2021)
- Issue Display:
- Volume 76, Issue 5 (2021)
- Year:
- 2021
- Volume:
- 76
- Issue:
- 5
- Issue Sort Value:
- 2021-0076-0005-0000
- Page Start:
- 1323
- Page End:
- 1331
- Publication Date:
- 2021-01-19
- Subjects:
- Anti-infective agents -- Periodicals
Chemotherapy -- Periodicals
615.58 - Journal URLs:
- http://jac.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/jac/dkaa563 ↗
- Languages:
- English
- ISSNs:
- 0305-7453
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4939.100000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25227.xml